 phase trial high-dos diaziquon autolog bone marrow transplant illinoi cancer council studi diaziquon azq synthet quinon demonstr activ acut nonlymphocyt leukemia anll primari cn tumor non-hodgkin lymphoma nhl devoid nonhematopoiet toxic convent dose prelud inclus bone marrow transplant bmt prepar regimen phase high-dos azq autolog bmt abmt patient refractori solid tumor lymphoma singl infus azq dose escal fifty-six patient cours granulocyt platelet count nausea stomat diarrhea mild transient dose-rel transient minim elev liver function test patient dose-rel dose mtd high-dos azq nephrotox dose-limit signific azotemia patient fatal anur renal failur patient revers proteinuria cours nephrot rang proteinuria cours dose proteinuria multipl proxim tubular defect aminoaciduria proxim renal tubular acidosi earli death earli renal failur sepsi pulmonari embolu progress diseas patient assess respons respons primari cn tumor malign melanoma non-small-cel lung carcinoma breast carcinoma ovarian carcinoma activ anll nhl uniqu toxic spectrum high-dos azq efficaci current bmt prepar regimen nonhematopoiet toxic